DOV KADMON to Antineoplastic Agents
This is a "connection" page, showing publications DOV KADMON has written about Antineoplastic Agents.
Connection Strength
0.302
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
Score: 0.140
-
Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8.
Score: 0.080
-
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
Score: 0.033
-
Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000; 18(5):429-38.
Score: 0.019
-
CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
Score: 0.007
-
Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. Cancer Res. 1984 Mar; 44(3):1034-40.
Score: 0.006
-
Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
Score: 0.006
-
Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1982 Apr; 42(4):1390-4.
Score: 0.006
-
Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate. 1982; 3(4):383-9.
Score: 0.005